Table 1.
Characteristics | AJCC stage IV uveal melanoma at initial presentation (group M) n=69 |
AJCC stage I–III uveal melanoma at initial presentation (group N) n=3541 |
|||||
Choroidal | Ciliary body | Iris | Choroidal | Ciliary body | Iris | ||
Sample | 55 (80%) | 11 (16%) | 3 (4%) | 3097 (87%) | 266 (8%) | 178 (5%) | |
Tumour thickness (mm) |
Mean (SD) | 8.3 (4.8) | 9.6 (3.4) | N/A | 5.7 (3.0) | 6.0 (3.0) | N/A |
Median (range) | 7.7 (2-0–24.5) | 11.0 (2.7–14.7) | N/A | 5.0 (2.0–23.0) | 5.6 (2.0–16.0) | N/A | |
Largest basal diameter (mm)* | Mean (SD) | 14.4 (4.7) | 10.2 (2.6) | 6.8 (2.0) | 12.1 (3.8) | 10.4 (2.8) | 3.9 (2.7) |
Median (range) | 15.0 (2.9–25.0) | 9.1 (6.0–13.8) | 6.4 (5.0–9.0) | 12.0 (2.0–30.0) | 11.0 (2.0–14.0) | 3.0 (0.5–19.0) | |
T-category | T1 | 5 (9%) | 1 (9%) | 2 (67%) | 944 (31%) | 87 (33%) | 92 (52%) |
T2 | 18 (33%) | 2 (18%) | 0 (0%) | 1101 (35%) | 107 (40%) | 84 (47%) | |
T3 | 16 (29%) | 7 (64%) | 0 (0%) | 832 (27%) | 67 (25%) | 0 (0%) | |
T4 | 16 (29%) | 1 (9%) | 1 (33%) | 220 (7%) | 5 (2%) | 2 (1%) | |
ESE | 6 (11%) | 5 (45%) | 1 (33%) | 48 (2%) | 16 (6%) | 2 (1%) | |
CBI | 11 (20%) | 11 (100%) | 1 (33%) | 248 (8%) | 266 (100%) | 88 (49%) | |
ESE and CBI | 4 (7%) | 5 (45%) | 1 (33%) | 20 (1%) | 16 (100%) | 2 (1%) |
*In the case of iris melanoma, only the largest basal diameter was mentioned.
AJCC, American Joint Committee on Cancer, 8th edition; CBI, ciliary body involvement; ESE, extrascleral extension.